NBTX Nanobiotix S.A.

Biotech Analyst Ratings

Latest News

1. 11 May 2022 NANOBIOTIX to Participate in Two Upcoming Investor Conferences

   Regulatory News:

   NANOBIOTIX (NASDAQ:NBTX, Company", ))), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in the following conferences:

   UBS Global Healthcare Conference

   • Presentation Date: Monday, May 23^rd, 2022
   • Time: 10:45 AM ET
   • Location: New York, New York, USA

   H.C. Wainwright Global Investment Conference

   • Presentation Date: Wednesday, May 25^th, 2022
   • Time: 8:30 AM ET
   • Location: Virtual and Miami, Florida, USA

   A live audio webcast of each presentation will be available on the events page of the Investors…

   View Full Article
2. 10 May 2022 Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company's Share Capital

   In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des Marchés Financiers (French Financial Markets Authority)

   Regulatory News:

   Nanobiotix (PARIS:NANO) (NASDAQ:NBTX):

   Market: Euronext Paris / Nasdaq
   Euronext Compartment: B
   ISIN code: FR0011341205
   Nasdaq: NBTX
   Bloomberg: NANO:FP
   Reuters: NANO.PA
   Website: www.nanobiotix.com

   Date	Number of Shares Outstanding	Total number of voting rights
   		Total voting rights, gross (1)	Total voting rights, net (2)
   April 30, 2022	34,875,872	36,392,064	36,371,073

   ⁽¹⁾ The total number of gross (or "theoretical") voting rights is used as the basis for calculating threshold crossings. In accordance with …

   View Full Article
3. 04 May 2022 NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022

   Regulatory News:

   NANOBIOTIX (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will report its financial results for the first quarter of 2022 ending March 31, 2022, on Wednesday, May 18, 2022, after the close of the US market.

   The announcement will be followed by a conference call and live audio webcast on Thursday, May 19, 2022, at 8:00 AM EDT / 2:00 CET, prior to the opening of the US market. During the call, Laurent Levy, chief executive officer, and Bart Van Rhijn, chief financial officer, will briefly review the Company's first quarter results and provide an update on operational activities before taking questions…

   View Full Article
4. 02 May 2022 New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual Meeting

   Regulatory News:

   NANOBIOTIX (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the presentation of three abstracts featuring potential first-in-class radioenhancer NBTXR3 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7.

   "We are aiming to significantly improve outcomes for patients with cancer through NBTXR3, and to do so we must validate the safety and efficacy of our innovation across solid tumor indications and in combination with existing treatment modalities," said Laurent Levy, co-founder and chief executive officer of Nanobiotix. "Taken together with data we have previously reported…

   View Full Article
5. 11 April 2022 NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3

   Data presented at the 2022 Annual Meeting of the American Association of Cancer Research

   • New data from an open-label preclinical study in mice evaluating the changes in immune-related genes induced by multiple combinations of NBTXR3, anti-PD-1, anti-LAG-3, and anti-TIGIT showed that groups that received NBTXR3 along with checkpoint inhibitors outperformed all other combinations in efficacy, survival, and induction of long-term anti-cancer memory
   • This new analysis concluded that NBTXR3 plus a triple blockade of PD-1, LAG-3, and TIGIT (Combination therapy) promotes immune activation at the irradiated site, abscopal responses at non-irradiated sites, and suggests that the Combination therapy may be effective against metastatic cancers

   Regulatory…

   View Full Article